CAR T-cell Therapy for Multiple Myeloma

Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy. It helps the body’s own immune system find and attack cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside certain immune cells to help them attack the cancer.

For this treatment, immune cells called T cells are removed from the patient’s blood and genetically altered in the lab so they have specific receptors (called chimeric antigen receptors, or CARs) on their surface. These receptors can attach to proteins on cancer cells. The T cells are then multiplied in the lab and given back into the person’s blood, where they can seek out the cancer cells and help the immune system attack them.

Idecabtagene vicleucel (Abecma)

Idecabtagene vicleucel (or ide-cel, for short) is a type of CAR T-cell therapy that targets the BCMA protein, which is found on myeloma cells. This treatment can be used in patients who have already received several (typically at least 4) other types of treatment for their multiple myeloma.

To make this treatment, T cells are taken from the person’s blood during a process called leukapheresis. Blood is removed through an IV line and goes into a machine that takes out the T cells. The remaining blood then goes back into the body. This process typically takes a few hours, and it might need to be repeated. The T cells are then frozen and sent to a lab, where they are turned into CAR T cells and are multiplied. This typically takes several weeks.

Once the CAR T cells are ready, the patient gets chemotherapy for a few days to help prepare the body. Then the CAR T cells are infused into a vein.

Possible side effects

This treatment can have serious or even life-threatening side effects, so it needs to be given in a medical center that is specially trained in its use. Your health care team will watch you closely for several weeks after you get the CAR T cells.

Cytokine release syndrome (CRS): CRS can happen when T cells release chemicals (cytokines) that ramp up the immune system. CRS most often happens within a few days to weeks after treatment, and in some cases it can be life-threatening. Symptoms can include:

  • High fever and chills
  • Trouble breathing
  • Severe nausea, vomiting, and/or diarrhea
  • Feeling dizzy or lightheaded
  • Headaches
  • Fast heartbeat
  • Feeling very tired

Nervous system problems: This treatment can sometimes have serious effects on the nervous system, which can result in symptoms such as:

  • Headaches
  • Changes in consciousness
  • Confusion or agitation
  • Seizures
  • Shaking or twitching (tremors)
  • Trouble speaking and understanding
  • Loss of balance

Because of the risk of these side effects, you’ll be advised not to drive, operate heavy machinery, or do any other potentially dangerous activities for at least 8 weeks after you get your treatment.

Other serious side effects: Other possible serious side effects can include:

  • Allergic reactions during the infusion
  • A weakened immune system
  • An increased risk of serious infections
  • Low blood cell counts, which can increase the risk of infections, fatigue, and bruising or bleeding

It’s very important to report any side effects to your health care team right away, as there are often medicines that can help treat them.

To learn more about this type of treatment, see CAR T-cell Therapy and Its Side Effects.

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Celgene Corporation. ABECMA US Prescribing Information. 2021. Accessed at https://www.fda.gov/media/147055/download on March 31, 2021.

References

Last Revised: March 31, 2021

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.